Abeome is an emerging biotechnology company dedicated
to leveraging its proprietary hybridoma technology
to accelerate and improve development of
monoclonal antibodies for life sciences and clinical medicine.
to leveraging its proprietary hybridoma technology
to accelerate and improve development of
monoclonal antibodies for life sciences and clinical medicine.
Abeome's DiSH technology is the key to
driving unprecedented efficiencies in
screening for new targets. Using DiSH,
desired monoclonals can be identified using
fluorescent-labeled antigens to bind surface-
expressed antibodies, making isolation and cloning desired cells significantly easier.
driving unprecedented efficiencies in
screening for new targets. Using DiSH,
desired monoclonals can be identified using
fluorescent-labeled antigens to bind surface-
expressed antibodies, making isolation and cloning desired cells significantly easier.
Research and identification of
novel/high potential monoclonal
antibodies is hampered by a
cumbersome, costly and inefficient
screening and cloning process.
novel/high potential monoclonal
antibodies is hampered by a
cumbersome, costly and inefficient
screening and cloning process.
